DACT3

Summary

DACT3 (dishevelled binding antagonist of beta catenin 3, HGNC:30745) is a protein-coding gene on chromosome 19q13.32, encoding Dapper homolog 3 (Q96B18). May be involved in regulation of intracellular signaling pathways during development.

Predicted to enable delta-catenin binding activity; protein kinase A binding activity; and protein kinase C binding activity. Involved in negative regulation of canonical Wnt signaling pathway and negative regulation of cell growth. Predicted to be active in cytoplasm.

Source: NCBI Gene 147906 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 118 total
• MANE Select transcript: NM_145056

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30745
Approved symbol	DACT3
Name	dishevelled binding antagonist of beta catenin 3
Location	19q13.32
Locus type	gene with protein product
Status	Approved
Aliases	MGC15476, DAPPER3
Ensembl gene	ENSG00000197380
Ensembl biotype	protein_coding
OMIM	611112
Entrez	147906

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000300875, ENST00000391916, ENST00000410105

RefSeq mRNA: 2 — MANE Select: NM_145056 NM_001301046, NM_145056

CCDS: CCDS12688, CCDS74402

Canonical transcript exons

ENST00000391916 — 4 exons

Exon	Start	End
ENSE00003540152	46647551	46649872
ENSE00003541849	46652660	46652812
ENSE00003690754	46652979	46653075
ENSE00003849607	46660816	46661182

Expression profiles

Bgee: expression breadth ubiquitous, 215 present calls, max score 96.93.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4415 / max 42.6396, expressed in 526 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181664	1.4226	521
181662	0.0189	11

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
popliteal artery	UBERON:0002250	96.93	gold quality
tibial artery	UBERON:0007610	96.93	gold quality
aorta	UBERON:0000947	96.33	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.18	gold quality
inferior vagus X ganglion	UBERON:0005363	96.08	gold quality
ascending aorta	UBERON:0001496	95.61	gold quality
thoracic aorta	UBERON:0001515	95.57	gold quality
dorsal plus ventral thalamus	UBERON:0001897	94.93	gold quality
descending thoracic aorta	UBERON:0002345	94.92	gold quality
right coronary artery	UBERON:0001625	94.84	gold quality
lateral nuclear group of thalamus	UBERON:0002736	94.69	gold quality
medial globus pallidus	UBERON:0002477	94.62	gold quality
globus pallidus	UBERON:0001875	94.59	gold quality
anterior cingulate cortex	UBERON:0009835	94.51	gold quality
subthalamic nucleus	UBERON:0001906	94.49	gold quality
ventral tegmental area	UBERON:0002691	94.23	gold quality
parietal lobe	UBERON:0001872	94.14	gold quality
saphenous vein	UBERON:0007318	94.08	gold quality
prefrontal cortex	UBERON:0000451	93.95	gold quality
postcentral gyrus	UBERON:0002581	93.85	gold quality
lateral globus pallidus	UBERON:0002476	93.67	gold quality
amygdala	UBERON:0001876	93.65	gold quality
Ammon’s horn	UBERON:0001954	93.36	gold quality
superior vestibular nucleus	UBERON:0007227	93.29	gold quality
frontal cortex	UBERON:0001870	93.20	gold quality
temporal lobe	UBERON:0001871	93.20	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.10	gold quality
midbrain	UBERON:0001891	93.07	gold quality
Brodmann (1909) area 9	UBERON:0013540	92.99	gold quality
substantia nigra	UBERON:0002038	92.96	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.96
E-ENAD-17	no	44.55
E-GEOD-70580	no	17.87
E-ENAD-27	no	3.79

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): EZH2, NKX2-5

miRNA regulators (miRDB)

55 targeting DACT3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-4685-5P	99.25	65.99	1563

Literature-anchored findings (GeneRIF, showing 3)

• Epigenetic repression of DACT3 leads to aberrant Wnt-beta-catenin signaling in colorectal cancer cells. (PMID:18538736)
• Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3. (PMID:33054518)
• DACT3 has a tumor-inhibiting role in acute myeloid leukemia via the suppression of Wnt/beta-catenin signaling by DVL2. (PMID:35187752)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	dact3a	ENSDARG00000087910
mus_musculus	Dact3	ENSMUSG00000078794
rattus_norvegicus	Dact3	ENSRNOG00000052256

Paralogs (2): DACT2 (ENSG00000164488), DACT1 (ENSG00000165617)

Protein

Protein identifiers

Dapper homolog 3 — Q96B18 (reviewed: Q96B18)

Alternative names: Antagonist of beta-catenin Dapper homolog 3, Arginine-rich region 1 protein, Dapper antagonist of catenin 3

All UniProt accessions (3): A0A0C4DFP1, G5E9H6, Q96B18

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in regulation of intracellular signaling pathways during development. Specifically thought to play a role in canonical and/or non-canonical Wnt signaling pathways through interaction with DSH (Dishevelled) family proteins.

Subunit / interactions. Can form homodimers and heterodimers with DACT1 or DACT3. Interacts with CSNK1D, PKA catalytic subunit, PKC-type kinase, DVL1, DVL3, VANGL1, VANGL2 and CTNND1. Interacts with DVL2.

Domain organisation. The C-terminal PDZ-binding motif may mediate interaction with the PDZ domains of DSH (Dishevelled) family proteins.

Similarity. Belongs to the dapper family.

RefSeq proteins (2): NP_001287975, NP_659493* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR024843	Dapper	Family

Pfam: PF15268

UniProt features (19 total): compositionally biased region 8, modified residue 6, region of interest 2, chain 1, coiled-coil region 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96B18-F1	53.51	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 6, 165, 239, 258, 426, 478

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 89 (showing top): BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, GOBP_NEGATIVE_REGULATION_OF_CELL_GROWTH, GOBP_GROWTH, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION, CHANDRAN_METASTASIS_DN, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, SRF_C, GOBP_MESENCHYMAL_CELL_DIFFERENTIATION, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, VDR_Q3, GOBP_MESENCHYME_DEVELOPMENT, CDPCR3HD_01

GO Biological Process (7): epithelial to mesenchymal transition (GO:0001837), negative regulation of epithelial to mesenchymal transition (GO:0010719), negative regulation of Wnt signaling pathway (GO:0030178), negative regulation of cell growth (GO:0030308), canonical Wnt signaling pathway (GO:0060070), negative regulation of canonical Wnt signaling pathway (GO:0090090), Wnt signaling pathway (GO:0016055)

GO Molecular Function (5): protein kinase C binding (GO:0005080), identical protein binding (GO:0042802), protein kinase A binding (GO:0051018), delta-catenin binding (GO:0070097), protein binding (GO:0005515)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	3
Wnt signaling pathway	2
mesenchymal cell differentiation	1
epithelial to mesenchymal transition	1
regulation of epithelial to mesenchymal transition	1
negative regulation of cell differentiation	1
negative regulation of multicellular organismal process	1
negative regulation of signal transduction	1
regulation of Wnt signaling pathway	1
regulation of cell growth	1
cell growth	1
negative regulation of growth	1
negative regulation of cellular process	1
negative regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
cell surface receptor signaling pathway	1
protein kinase binding	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

488 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DACT3	DACT2	Q5SW24	924
DACT3	DVL2	O14641	618
DACT3	CTNNB1	P35222	600
DACT3	EZH2	Q15910	498
DACT3	AXIN1	O15169	489
DACT3	CDK13	Q14004	474
DACT3	ZNF503	Q96F45	462
DACT3	SNX8	Q9Y5X2	422
DACT3	MEX3B	Q6ZN04	410
DACT3	DUSP11	O75319	409
DACT3	DACT1	Q9NYF0	408
DACT3	DVL1	O14640	404
DACT3	ADAR	P55265	384
DACT3	SUGP2	Q8IX01	365
DACT3	ARIH2OS	Q8N7S6	365

IntAct

11 interactions, top by confidence:

A	B	Type	Score
DUSP3	ERLIN1	psi-mi:“MI:0914”(association)	0.530
DACT3	PKD2	psi-mi:“MI:0914”(association)	0.350
DACT3	GALE	psi-mi:“MI:0914”(association)	0.350
ORF33	ATN1	psi-mi:“MI:0914”(association)	0.350
DACT3	GIGYF1	psi-mi:“MI:0915”(physical association)	0.000
KSR1	DACT3	psi-mi:“MI:0915”(physical association)	0.000
DACT3	KIF13B	psi-mi:“MI:0915”(physical association)	0.000
DACT3	ZBTB21	psi-mi:“MI:0915”(physical association)	0.000
DACT3	CBY1	psi-mi:“MI:0915”(physical association)	0.000
DACT3	KCTD3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (21): KCTD3 (Affinity Capture-MS), KIF13B (Affinity Capture-MS), ZBTB21 (Affinity Capture-MS), DACT3 (Affinity Capture-MS), GIGYF1 (Affinity Capture-MS), CBY1 (Affinity Capture-MS), DACT3 (Two-hybrid), DACT3 (Affinity Capture-RNA), DACT3 (Affinity Capture-RNA), SLC38A2 (Affinity Capture-MS), SESTD1 (Affinity Capture-MS), DACT3 (Affinity Capture-MS), IFT22 (Affinity Capture-MS), PKD2 (Affinity Capture-MS), TRAT1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0U1RQ45, A0A0U1RQS6, A0A2R8YCJ5, A2A699, A2AEV7, A6NGB7, A6NJG2, A6NKF7, A6NKL6, A6NL88, A8MVW0, A9JSM3, B2RU40, B8ZZ34, C9JH25, D4A9R4, J3QNX5, P0CG09, P98077, Q0VD38, Q14761, Q17QH7, Q29RK8, Q2KJ18, Q2M3V2, Q3SX20, Q5BJT1, Q5HZJ5, Q5RKR3, Q5T442, Q64697, Q69YZ2, Q6PB97, Q6PCT2, Q6UXK2, Q6ZMQ8, Q6ZVH7, Q6ZW31, Q80XF7, Q8BLS7

Diamond homologs: Q0PHV7, Q66KC9, Q6QZN6, Q8JJ48, Q8QG92, Q8R4A3, Q96B18, Q9NYF0, Q5SW24, Q673G8, Q7TN08

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
EZH2	“down-regulates quantity by repression”	DACT3	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

118 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	116
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

423 predictions. Top by Δscore:

Variant	Effect	Δscore
19:46652810:AGCC:A	acceptor_loss	1.0000
19:46652813:C:CC	acceptor_gain	1.0000
19:46652814:T:C	acceptor_loss	1.0000
19:46652822:C:CT	acceptor_gain	1.0000
19:46652996:T:A	donor_gain	1.0000
19:46653073:CTC:C	acceptor_gain	1.0000
19:46653083:C:CT	acceptor_gain	1.0000
19:46653084:A:AC	acceptor_gain	1.0000
19:46653084:A:C	acceptor_gain	1.0000
19:46660810:CCTTA:C	donor_loss	1.0000
19:46660811:CTTAC:C	donor_loss	1.0000
19:46660812:TTACC:T	donor_loss	1.0000
19:46660813:TACC:T	donor_loss	1.0000
19:46660814:A:AC	donor_gain	1.0000
19:46660815:C:CC	donor_gain	1.0000
19:46660815:C:CT	donor_loss	1.0000
19:46660815:CCAG:C	donor_gain	1.0000
19:46649870:CTC:C	acceptor_gain	0.9900
19:46649888:C:CT	acceptor_gain	0.9900
19:46649889:A:T	acceptor_gain	0.9900
19:46652655:CTTAC:C	donor_loss	0.9900
19:46652656:TTA:T	donor_loss	0.9900
19:46652658:AC:A	donor_loss	0.9900
19:46652659:CCTAG:C	donor_loss	0.9900
19:46652679:A:AC	donor_gain	0.9900
19:46652680:C:CC	donor_gain	0.9900
19:46652808:GAAGC:G	acceptor_gain	0.9900
19:46652811:GC:G	acceptor_gain	0.9900
19:46652812:CC:C	acceptor_gain	0.9900
19:46652822:C:T	acceptor_gain	0.9900

AlphaMissense

3905 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:46648492:G:A	T627I	1.000
19:46648494:C:A	M626I	1.000
19:46648494:C:G	M626I	1.000
19:46648494:C:T	M626I	1.000
19:46648495:A:G	M626T	1.000
19:46648500:C:A	K624N	1.000
19:46648500:C:G	K624N	1.000
19:46648504:A:G	L623P	1.000
19:46648504:A:T	L623H	1.000
19:46648518:G:C	F618L	1.000
19:46648518:G:T	F618L	1.000
19:46648519:A:C	F618C	1.000
19:46648519:A:G	F618S	1.000
19:46648520:A:C	F618V	1.000
19:46648520:A:G	F618L	1.000
19:46648520:A:T	F618I	1.000
19:46648528:A:C	I615R	1.000
19:46648528:A:G	I615T	1.000
19:46648528:A:T	I615K	1.000
19:46648534:T:A	K613I	1.000
19:46648536:C:A	K612N	1.000
19:46648536:C:G	K612N	1.000
19:46648537:T:A	K612M	1.000
19:46648538:T:C	K612E	1.000
19:46648540:A:G	L611P	1.000
19:46648540:A:T	L611H	1.000
19:46648549:G:A	S608F	1.000
19:46648552:G:T	A607D	1.000
19:46648554:T:A	K606N	1.000
19:46648554:T:G	K606N	1.000

dbSNP variants (sampled 300 via entrez): RS1000002893 (19:46655030 TA>T,TAA,TAAA), RS1000382144 (19:46652051 G>A), RS1000489805 (19:46658126 C>T), RS1000541420 (19:46647257 A>C), RS1000602364 (19:46653948 T>C), RS1000708362 (19:46659143 G>A,C), RS1000938898 (19:46661158 T>C,G), RS1001044429 (19:46648005 G>A), RS1001120849 (19:46653556 T>TTTA), RS1001126456 (19:46660359 T>A), RS1001272109 (19:46651066 T>TATTC), RS1001436581 (19:46654212 C>T), RS1001783597 (19:46650824 C>T), RS1002616367 (19:46662046 CT>C), RS1002995422 (19:46657308 C>A,T)

Disease associations

OMIM: gene MIM:611112 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	increases expression	3
Tobacco Smoke Pollution	increases expression	2
Tretinoin	increases expression	2
Valproic Acid	increases expression, increases methylation	2
aristolochic acid I	increases expression	1
OTX015	increases expression	1
FR900359	decreases phosphorylation	1
mivebresib	increases expression	1
propionaldehyde	increases expression	1
trichostatin A	affects methylation, affects acetylation, affects cotreatment, affects expression	1
butyraldehyde	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
beta-methylcholine	affects expression	1
pentanal	increases expression	1
3-deazaneplanocin	affects expression, affects acetylation, affects cotreatment, affects methylation	1
abrine	increases expression	1
licochalcone B	increases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Decitabine	affects expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Aldehydes	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Calcitriol	decreases expression	1
Cisplatin	increases expression	1
Dexamethasone	decreases expression	1
Doxorubicin	decreases expression	1
Hydrogen Peroxide	affects cotreatment, decreases expression	1
Lead	affects expression	1
Lipopolysaccharides	increases expression, affects response to substance	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders